EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Dec. 13, 2005--Savient Pharmaceuticals, Inc. (NASDAQ: SVNTE) an emerging specialty pharmaceuticals company focused on developing, manufacturing and marketing novel therapeutic products for unmet medical needs, announced today that the Company has agreed to sell its injectable testosterone product for male hypogonadism, Delatestryl(R), to Indevus Pharmaceuticals Inc., of Lexington Mass. The closing of the transaction, which has been approved by the boards of directors of both companies, is subject to certain conditions. Savient expects that the transaction will close early in 2006.
